Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity.

Cell Immunol. 1999 Nov 25;198(1):69-75. Unique Identifier : AIDSLINE MED/20080784
Kobayashi H; Horner AA; Takabayashi K; Nguyen MD; Huang E; Cinman N; Raz E; Department of Medicine, University of California at San Diego,; 9500 Gilman Drive, La Jolla, California 92093-0663, USA.

Abstract: Immunostimulatory DNA sequences (ISS) have been shown to promote CTL and Th1 immune responses to coinjected antigens. This phenomenon can be attributed to the capacity of ISS to induce the secretion of type-1 cytokines and to up regulate costimulatory ligands on antigen-presenting cells. We hypothesized that ISS administration prior to antigen administration (prepriming), via the mechanisms stated above, would Th1 bias immune responses to subsequently injected antigens for an extended period of time. The data presented show that ISS provide in vivo adjuvant activity for up to 2 weeks after intradermal or intranasal delivery. Furthermore, the results demonstrate that ISS prepriming can induce immune responses that are significantly stronger than with ISS/antigen covaccination. ISS prepriming offers an alternative approach to the traditional use of adjuvants (i.e., antigen/adjuvant coinjection) and expands the potential clinical applications for ISS. Copyright 1999 Academic Press.

Keywords: JOURNAL ARTICLE Adjuvants, Immunologic/*ADMINISTRATION & DOSAGE/*GENETICS Administration, Intranasal Animal CpG Islands/IMMUNOLOGY DNA, Bacterial/ADMINISTRATION & DOSAGE/*IMMUNOLOGY Female IgA/BIOSYNTHESIS Injections, Intradermal Injections, Intraperitoneal *Lymphocyte Transformation/GENETICS Mice Mice, Inbred BALB C Nasal Mucosa/IMMUNOLOGY Oligodeoxyribonucleotides/ADMINISTRATION & DOSAGE/GENETICS/ IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Thionucleotides/ADMINISTRATION & DOSAGE/GENETICS/IMMUNOLOGY Th1 Cells/*IMMUNOLOGY Time Factors

KWDjournalarticleadjuvants,immunologic/KWDadministration&dosage/KWDgeneticsadministration,intranasalanimalcpgislands/immunologydna,bacterial/administration&dosage/KWDimmunologyfemaleiga/biosynthesisinjections,intradermalinjections,intraperitonealKWDlymphocytetransformation/geneticsmicemice,inbredbalbcnasalmucosa/immunologyoligodeoxyribonucleotides/administration&dosage/genetics/immunologysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDthionucleotides/administration&dosage/genetics/immunologyth1cells/KWDimmunologytimefactors
000430
A0040893

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .